US Pharma MarketingNovartis pushes ahead with its IL-6 inhibitor despite Novo’s failure
Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the…
MUNICH — Novartis is to kick off a Phase 3 trial to see whether its anti–IL‑6 antibody can prevent cardiovascular (CV) events in people with elevated CV risk by reducing inflammation, despite the failure of ...
Source: Endpoints News